 NASHVILLE, Tenn. TOKYO--BUSINESS WIRE--- HROW--Harrow Health, Inc. NASDAQ: HROW, an ophthalmicfocused healthcare company, today announced that it has entered into an agreement with Wakamoto Pharmaceutical Co., Ltd. to acquire the U.S. and Canadian commercial rights for drug candidate MAQ-100, a preservative-free triamcinolone acetonide ophthalmic injection. MAQ-100 is marketed and sold by Wakamoto in Japan as MaQaid. Following Japans Ministry of Health Labor and Welfare or MHLW approval, MaQ 